Skip to main content
Locate a specialist
Patient and carer information
Health professional information

ASCIA News

  • Vale Dr Rob Loblay MBBS PhD FRACP - October 2024
    It is with great sadness we learnt that Dr Rob Loblay MBBS PhD FRACP passed away in early October 2024.  Dr Rob Loblay made significant contributions to ASCIA, particularly in the area of anaphylaxis management during his time as Chair of the ASCIA Anaphylaxis working...
  • Vale A/Prof Dan Czarny MBBS FRACP FRCP - May 2024
    It is with great sadness we learnt that A/Prof Dan Czarny MBBS FRACP FRCP passed away in early May 2024 at the age of 84.   A/Prof Dan Czarny made significant contributions to ASCIA, particularly as the 2nd ASCIA Past President from 1992 to 1994, after ASCIA was formed in...
  • New PBS Listed Treatment for ANCA Associated Vasculitis - October 2024
    In response to an application by CSL Seqirus to the Pharmaceutical Benefits Advisory Committee (PBAC), the Pharmaceutical Benefits Scheme (PBS) listing of Tavneos® (avacopan) that was recommended by the PBAC in March 2024 has come into effect on 1 October 2024. This...
  • Biologics in Severe Asthma - Change in PBS Criteria - October 2024
    In response to an application by GSK to the Pharmaceutical Benefits Advisory Committee (PBAC) to remove the oral corticosteroid (OCS) requirement to qualify for biologics in uncontrolled severe asthma, the Pharmaceutical Benefits Scheme (PBS) OCS criteria change that was...
  • ASCIA 2024 Conference Report
    The ASCIA 2024 Conference was held from Tuesday 3rd to Friday 6th September 2024 at the Adelaide Convention Centre. This was a hybrid conference, which enabled virtual or in-person attendance, and on-demand viewing of sessions for all registered delegates for up to six...
  • ASCIA Annual General Meeting 2024
    A total of 117 ASCIA members (81 in-person and 36 online) attended the ASCIA Annual General Meeting (AGM) which was held during the ASCIA 2024 Conference week, on Thursday 5 September 2024, at the Adelaide Convention Centre,   The ASCIA AGM 2024 Minutes are available on the...
  • Shingrix Vaccine to Prevent Shingles - September 2024 Update
    Shingrix®  is a varicella zoster virus recombinant vaccine that can provide protection from herpes zoster (shingles) and post-herpetic neuralgia (long-term nerve pain).  Further to ASCIA advocating for funded access to Shingrix®  for people with immune deficiencies on the...
  • Updated ASCIA OIT for Food Allergy FAQ
    ASCIA Oral Immunotherapy (OIT) for Food Allergy Frequently Asked Questions (FAQ) for patients and carers has been updated to include more information about safety concerns. The updated FAQ is available on the ASCIA website...
More ASCIA News
ASCIA Member Login
Site last updated: 3 Oct 2024
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.

Join our mailing list or see latest edition here...